Lunai Bioworks Inc. (LNAI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Lunai Bioworks Inc. (LNAI) has a cash flow conversion efficiency ratio of 0.079x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.07 Million) by net assets ($-13.55 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Lunai Bioworks Inc. to measure how much of total assets are equity-financed.
Lunai Bioworks Inc. - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Lunai Bioworks Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check LNAI cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Lunai Bioworks Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lunai Bioworks Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Group One Capital Limited
AU:G1C
|
0.083x |
|
Merchants Trust PLC
LSE:MRCH
|
0.019x |
|
AIR INDUSTRIES GR.DL-001
F:YH1
|
-0.031x |
|
Elicera Therapeutics AB
ST:ELIC
|
-0.156x |
|
Phio Pharmaceuticals Corp
NASDAQ:PHIO
|
-0.243x |
|
Astute Metals NL
AU:ASE
|
-0.011x |
|
Cocrystal Pharma Inc
NASDAQ:COCP
|
-0.569x |
|
GMV Minerals Inc
V:GMV
|
-0.023x |
Annual Cash Flow Conversion Efficiency for Lunai Bioworks Inc. (2021–2025)
The table below shows the annual cash flow conversion efficiency of Lunai Bioworks Inc. from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see Lunai Bioworks Inc. (LNAI) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $-21.35 Million | $-7.87 Million | 0.369x | +543.68% |
| 2024-06-30 | $131.98 Million | $-10.97 Million | -0.083x | +67.17% |
| 2023-06-30 | $46.50 Million | $-11.77 Million | -0.253x | -16.88% |
| 2022-06-30 | $72.62 Million | $-15.73 Million | -0.217x | -83.59% |
| 2021-06-30 | $174.66 Million | $-20.61 Million | -0.118x | -- |
About Lunai Bioworks Inc.
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; a… Read more